Acasti awarded Chinese krill patent as it eyes Far East expansion
There is an unmet need for well-studied and differentiated krill products in China, the world’s third largest pharmaceutical market, which has been seeing an annual growth rate of around 20% over the past decade
Acasti’s patent relates to concentrated therapeutic phospholipid omega-3 compositions and covers methods for treating or preventing diseases associated with cardiovascular diseases, metabolic syndrome, inflammation, and neurodevelopmental and neurodegenerative diseases.
"To date, Acasti has received patents in the United States, Australia, Panama and South Africa for its phospholipid composition," said Benoit Huart, the company’s legal affairs director, adding that Acasti has other patents pending in more than 40 jurisdictions.
"Today's announcement protects a vast market and provides potential expansion opportunities for our products," said Pierre Lemieux, Acasti's chief operating officer.